A robust pipeline of therapeutic candidates is emerging for pulmonary sarcoidosis patients, with more than 10 pharmaceutical companies actively developing novel treatments, according to a new report from DelveInsight released in January 2025.
Leading Therapeutic Candidates
Among the most promising candidates, Novartis's CMK389 is advancing through Phase II clinical trials. The drug works as an interleukin 18 inhibitor, targeting a key inflammatory pathway involved in sarcoidosis progression.
aTyr Pharma's ATYR1923 represents another significant advancement in the field. This potential first-in-class therapy selectively modulates Neuropilin-2 (NRP2) to control both innate and adaptive immune responses in inflammatory conditions. The drug is currently being evaluated in a Phase 1b/2a clinical trial for pulmonary sarcoidosis, a major form of interstitial lung disease.
Expanding Treatment Landscape
Bristol-Myers Squibb has also entered the space with BMS-986278, launching a study to evaluate its efficacy, safety, and tolerability in patients with Progressive Pulmonary Fibrosis. Other key players in the pipeline include Relief Therapeutics, AI Therapeutics, and SarcoMed USA, each pursuing unique therapeutic approaches.
Diverse Therapeutic Approaches
The pipeline encompasses various drug delivery methods, including oral, subcutaneous, and infusion routes. Therapeutic modalities range from small molecules to monoclonal antibodies and peptides, reflecting the complex nature of pulmonary sarcoidosis and the multiple pathways being targeted for treatment.
Clinical Development Status
Current clinical trials span multiple phases, from early discovery to Phase II studies. This robust development pipeline suggests a significant expansion of treatment options may be available to patients in the coming years, potentially addressing current therapeutic limitations in pulmonary sarcoidosis management.
